ORIC Pharmaceuticals, Inc.
ORIC
$8.60
-$0.23-2.61%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.29% | 14.41% | 10.99% | 20.32% | 14.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.09% | -12.68% | -4.30% | 8.46% | 12.86% |
| Operating Income | -21.09% | 12.68% | 4.30% | -8.46% | -12.86% |
| Income Before Tax | -19.14% | 15.98% | 5.73% | -13.74% | -20.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.14% | 15.98% | 5.73% | -13.74% | -20.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.14% | 15.98% | 5.73% | -13.74% | -20.03% |
| EBIT | -21.09% | 12.68% | 4.30% | -8.46% | -12.86% |
| EBITDA | -21.39% | 12.82% | 4.38% | -8.42% | -12.83% |
| EPS Basic | 19.76% | 42.13% | 32.80% | -2.40% | -13.79% |
| Normalized Basic EPS | 19.77% | 42.12% | 32.81% | -2.39% | -13.79% |
| EPS Diluted | 19.76% | 42.13% | 32.80% | -2.40% | -13.79% |
| Normalized Diluted EPS | 19.77% | 42.12% | 32.81% | -2.39% | -13.79% |
| Average Basic Shares Outstanding | 48.47% | 45.20% | 40.27% | 11.06% | 5.48% |
| Average Diluted Shares Outstanding | 48.47% | 45.20% | 40.27% | 11.06% | 5.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |